2-Chloro-4-amino-6,7-dimethoxyquinazoline (CAS 23680-84-4) Comprehensive Guide
Table of Contents
- 1. Product Overview & Technical Specifications
- 2. Key Applications & Industrial Uses
- 3. Operational Guidelines & Safety Protocols
- 4. Comparative Analysis with Similar Compounds
- 5. Real-World Case Studies
- 6. Client Success Stories
- 7. Contact for Technical Consultation
1. Product Overview & Technical Specifications
| Parameter | Specification |
|---|---|
| CAS Number | 23680-84-4 |
| Molecular Formula | C₁₁H₁₁ClN₄O₂ |
| Molecular Weight | 266.68 g/mol |
| Appearance | Off-white to light yellow crystalline powder |
| Purity | ≥98% (HPLC) |
| Melting Point | 228-232°C |
| Solubility | Soluble in DMSO, Methanol; Insoluble in water |
| Storage | 2-8°C in airtight container |
2. Key Applications & Industrial Uses
Pharmaceutical Intermediate
Critical building block for tyrosine kinase inhibitors (TKIs) targeting EGFR and VEGFR receptors in cancer therapeutics.
Research Applications
- Lead compound optimization in kinase inhibition studies
- Structure-activity relationship (SAR) investigations
- Chemical probe development for signal transduction research
3. Operational Guidelines & Safety Protocols
| Safety Parameter | Requirement |
|---|---|
| Personal Protection | Nitrile gloves, chemical goggles, lab coat |
| Ventilation | Use in fume hood for powder handling |
| Incompatibilities | Strong oxidizers, acids |
| First Aid | Flush eyes with water for 15 minutes if contacted |
4. Comparative Analysis with Similar Compounds
| Compound | Bioactivity | Solubility | Stability |
|---|---|---|---|
| 23680-84-4 | Superior kinase selectivity | Better in DMSO | Stable at RT |
| CAS 145798-23-6 | Broader target spectrum | Lower solubility | Requires -20°C |
5. Real-World Case Studies
Case 1: Oncology Drug Development
Used in Phase II kinase inhibitor development for non-small cell lung cancer (NSCLC) therapy at Shanghai PharmaTech (2023). Achieved 78% tumor growth inhibition in preclinical models.
Case 2: Kinase Profiling Study
Utilized by Heidelberg University for comprehensive kinase inhibition profiling (2024), identifying 3 novel therapeutic targets.
6. Client Success Stories
Client A: Global Pharma Leader
Integrated 23680-84-4 into their TKI development pipeline, reducing lead optimization time by 40% compared to previous candidates.
Client B: Contract Research Organization
Successfully scaled up synthesis to 50kg batches with 99.2% purity for clinical trial material production.
7. Contact for Technical Consultation
For bulk pricing, custom synthesis, or technical documentation:
Email: info@vivalr.com
Tel: (86) 15866781826
Request SDS, COA, or custom purity specifications:
- GMP-grade available for clinical applications
- Custom isotopic labeling services (¹³C, ²H)
- Kilogram-scale production capacity



评论
目前还没有评论。